Skip to main content

Table 2 General and pharmacokinetic characteristics of CGRP(-receptor) targeted mAbs [89]. Abbreviations: CGRP = calcitonin gene-related peptide; mAbs = monoclonal antibodies

From: The sense of stopping migraine prophylaxis

 

Molecular target

Indications

Administration route

Recommended dose and frequency

Half-life

Erenumab

CGRP receptor

Preventive treatment

subcutaneous

70 or 140 mg, monthly

28 days

Fremanezumab

CGRP

Preventive treatment

subcutaneous

225 mg (monthly), 675 mg (quarterly)

31 days

Galcanezumab

CGRP

Preventive treatment

subcutaneous

120 mg (first dose 240 mg), monthly

27 days

Eptinezumab

CGRP

Preventive treatment

intravenous

100 or 300 mg, quarterly

27 days